On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

The Fukushima Daiichi nuclear power plant's radiation levels have significantly dropped since the cataclysmic meltdown 14 ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Fourteen years after the Fukushima Daiichi meltdown, radiation levels have decreased, but decommissioning efforts remain ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Daiichi Sankyo meanwhile has started a phase 3 trial of another ADC – patritumab deruxtecan – comparing the drug to chemotherapy as a second-line therapy for EGFR-mutated advanced non-squamous ...

Following its demutualization and IPO in 2010, Daiichi Life Group has transformed from one of Japan’s big four traditional life insurers to a multinational holding company with a multibrand ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target ...